Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia

1. A compound of formula (I):

wherein:

R v is selected from hydrogen or C 1-6 alkyl;

One of R 1 and R 2 are selected from hydrogen, C 1-6 alkyl or C 2-6 alkenyl and the other is selected from C 1-6 alkyl or C 2-6 alkenyl;

R x and R y are independently selected from hydrogen, hydroxy, amino, mercapto, C 1-6 alkyl, C 1-6 alkoxy, N-(C 1-6 alkyl)amino, N,N-(C 1-6 alkyl) 2 amino, C 1-6 alkylS(O) a wherein a is 0 to 2;

M is selected from —N— or —CH—;

R z is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, N,N-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, N,N-(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N-(C 1-6 alkyl)sulphamoyl and N,N-(C 1-6 alkyl) 2 sulphamoyl;

v is 0–5;

one of R 4 and R 5 is a group of formula (IA):

R 3 and R 6 and the other of R 4 and R 5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a , wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl and N,N-(C 1-4 alkyl) 2 sulphamoyl; wherein R 3 and R 6 and the other of R 4 and R 5 may be optionally substituted on carbon by one or more R 16 ;

X is —O—, —N(R a )—, —S(O) b — or —CH(R a )—; wherein R a is hydrogen or C 1-6 alkyl and b is 0–2;

Ring A is aryl or heteroaryl; wherein Ring A is optionally substituted by one or more substituents selected from R 17 ;

R 7 is hydrogen, C 1-4 alkyl, carbocyclyl or heterocyclyl; wherein R 7 is optionally substituted by one or more substituents selected from R 18 ;

R 8 is hydrogen or C 1-4 alkyl;

R 9 is hydrogen or C 1-4 alkyl;

R 10 is hydrogen, C 1-4 alkyl, carbocyclyl or heterocyclyl; wherein R 10 is optionally substituted by one or more substituents selected from R 19 ;

R 11 is carboxy, sulpho, sulphino, phosphono, —P(O)(OR c )(OR d ), —P(O)(OH)(OR c ), —P(O)(OH)(R d ) or —P(O)(OR c )(R d ) wherein R c and R d are independently selected from C 1-6 allkyl; or R 11 is a group of formula (IB) or (IC):

R 19 , R 20 , R 24 and R 26 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkanoyloxy, N-(C 1-4 alkyl)amino, N,N-(C 1-4 alkyl) 2 amino, C 1-4 alkanoylamino, N-(C 1-4 alkyl)carbamoyl, N,N-(C 1-4 alkyl) 2 carbamoyl, C 1-4 alkylS(O) a wherein a is 0 to 2, C 1-4 alkoxycarbonyl, N-(C 1-4 alkyl)sulphamoyl, N,N-(C 1-4 alkyl) 2 sulphamoyl, carbocyclyl, heterocyclyl, benzyloxycarbonylamino, (C 1-4 alkyl) 3 silyl, sulpho, sulphino, amidino, phosphono, —P(O)(OR a )(OR b ), —P(O)(OH)(OR a ), —P(O)(OH)(R a ) or —P(O)(OR a )(R b ), wherein R a and R b are independently selected from C 1-6 alkyl; wherein R 19 , R 20 , R 24 and R 26 may be independently optionally substituted on carbon by one or more R 22 ;

R 21 and R 22 are independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, tifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxy, methylamino, dimethylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, methylthio, methylsulphinyl, mesyl, N-methylsulphamoyl and N,N-dimethylsulphamoyl;

R 23 is carboxy, sulpho, sulphino, phosphono, —P(O)(OR g )(OR h ), —P(O)(OH)(OR g ), —P(O)(OH)(R g ) or —P(O)(OR g )(R h ) wherein R g and R h are independently selected from C 1-6 alkyl;

R 25 is selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N-(C 1-6 alkyl)carbamoyl, N,N-(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

wherein “heteroaryl” is a totally unsaturated, mono or bicyclic ring containing 3–12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked;

wherein a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3–12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a CH 2 group can optionally be replaced by a C(O) or a ring sulphur atom may be optionally oxidised to form the S oxides; and

wherein a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3–12 atoms; wherein a CH 2 group can optionally be replaced by a C(O);

or a pharmaceutically acceptable salt thereof.

2. A compound of formula (I) as claimed in claim 1 wherein R v is hydrogen or a pharmaceutically acceptable salt thereof.

3. A compound of formula (I) as claimed in claim 1 wherein R 1 and R 2 are both butyl or a pharmaceutically acceptable salt thereof.

4. A compound of formula (I) as claimed in claim 1 wherein R x and R y are both hydrogen or a pharmaceutically acceptable salt thereof.

5. A compound of formula (I) as claimed in claim 1 wherein M is —N— or a pharmaceutically acceptable salt thereof.

6. A compound of formula (I) as claimed in claim 1 wherein v is 0 or a pharmaceutically acceptable salt thereof.

7. A compound of formula (I) as claimed in claim 1 wherein R 3 and R 6 are hydrogen or a pharmaceutically acceptable salt thereof.

8. A compound of formula (I) as claimed in claim 1 wherein R 4 is bromo, methyl or methylthio or a pharmaceutically acceptable salt thereof.

9. A compound of formula (I) as claimed in claim 1 wherein R 5 is a group of formula (IA) (as depicted in claim 1 ) wherein:

X is —O—;

Ring A is phenyl optionally substituted by one or more substituents selected from R 17 ;

n is 1;

R 7 is hydrogen;

R 8 is hydrogen;

R 9 is hydrogen;

m is 0;

R 11 is carboxy, a group of formula (IB) (as depicted above) or a group of formula (IC) (as depicted above) wherein:

R 12 is hydrogen or C 1-4 alkyl;

p is 1 or 2;

R 13 is hydrogen or C 1-6 alkyl optionally substituted by R 20 wherein R 20 is hydroxy, carbamoyl, amino, benzyloxycarbonylamino, C 1-4 alkylS(O) a wherein a is 0 or (C 1-4 alkyl) 3 silyl;

R 14 is hydrogen or hydroxy or C 1-6 alkyl; wherein R 14 may be optionally substituted by one or more substituents selected from R 20 ;

Y is —N(R n )C(O)— wherein R n is hydrogen;

q is 0 or 1;

r is 0 or 1;

R 15 is carboxy or sulpho;

R 17 is hydroxy; and

R 20 is selected from hydroxy;

Ring B is pyrrolidin-1-yl or azetidinyl substituted on carbon by one group selected from R 23 , and optionally additionally substituted on carbon by one or more R 24 ; wherein R 23 is carboxy and R 24 is hydroxy;

or a pharmaceutically acceptable salt thereof.

10. A compound of formula (I) as claimed in claim 1 wherein:

R v is hydrogen;

R 1 and R 2 are both butyl;

R x and R y are both hydrogen;

M is —N—;

v is 0;

R 3 and R 6 are hydrogen;

R 4 is bromo, methyl or methylthio; and

R 5 is N-{(R)-α-[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-2-hydroxyethyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxyethyl) carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-2-carbamoyl-ethyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-( 2 -sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-(carboxymethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-2-hydroxyethyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-(2-sulphoethyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy- 3 -methylbutyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-(1-(S)-1-carboxy-2-(S)-2-methylbutyl)carbamoyl]benzyl}carbamoylmethoxy, N-((R)-α-carboxy-4-hydroxybenzyl)carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-4-aminobutyl)carbamoyl]benzyl}carbamoylmethoxy, N-((R)-α-{N-[(S)-1-carboxy-4-(benzyloxycarbonylamino)butyl]carbamoyl}benzyl)carbamoylmethoxy, N-[(R)-α-((S)-2-carboxypyrrolidin-1-ylcarbonyl)benzyl]carbamoylmethoxy, N-{(R)-α-[N-(carboxymethyl)-N-methylcarbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-(1-(R)-2-(R)-1-carboxy-1-hydroxyprop-2-yl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-(sulphomethyl)carbamoyl]benzyl}carbamoylmethoxy, N-((R)-α-carboxybenzyl)carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-{(R)-α-[N-{(S)-1-[N-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[2-(S)-2-(carboxy)-4-(R)-4-(hydroxy)pyrrolidin-1-ylcarbonyl]benzyl}carbamoylmethoxy, N-{(R)-α-[2-(S)-2-(carboxy)azetidin-1-ylcarbonyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-{(S)-1-[N-((S)-1-carboxyethyl)carbamoyl]ethyl}carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((R)-1-carboxy-3,3-dimethylbutyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((S)-1-carboxy-3,3-dimethylbutyl)carbamoyl]benzyl}carbamoylmethoxy, N-{(R)-α-[N-((R)-1-carboxy-3,3-dimethylbutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy, N-((R)-α-{N-[(S)-1-carboxy-2-(trimethylsilyl)ethyl]carbamoyl}-4-hydroxybenzyl)carbamoylmethoxy or N-((R)-α-{N-[(R)-1-carboxy-2-(trimethylsilyl)ethyl]carbamoyl}-4-hydroxybenzyl)carbamoylmethoxy;

or a pharmaceutically acceptable salt thereof.

11. A compound of formula (I) as claimed in claim 1 selected from:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxybutyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-{(S)-1-[N-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

or a pharmaceutically acceptable salt thereof.

12. A process for preparing a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof which process comprises of:

Process 1): for compounds of formula (I) wherein X is —O—, —NR a or —S—; reacting a compound of formula (IIa) or (IIb):

 with a compound of formula (III):

 wherein L is a displaceable group;

Process 2): reacting an acid of formula (IVa) or (IVb):

 or an activated derivative thereof; with an amine of formula (V):

Process 3): for compounds of formula (I) wherein R 11 is a group of formula (IB); reacting a compound of formula (I) wherein R 11 is carboxy with an amine of formula (VI):

Process 4) for compounds of formula (I) wherein one of R 4 and R 5 are independently selected from C 1-6 alkylthio optionally substituted on carbon by one or more R 17 ; reacting a compound of formula (VIIa) or (VIlb):

 wherein L is a displaceable group; with a thiol of formula (VIII):

R m —H  (VIII)

 wherein R m is C 1-6 alkylthio optionally substituted on carbon by one or more R 16 ;

Process 5): for compounds of formula (I) wherein R 11 is carboxy, deprotecting a compound of formula (IXa):

 wherein R p together with the —OC(O)— group to which it is attached forms an ester;

Process 6): for compounds of formula (I) wherein R 11 is a group of formula (IB) and R 15 is carboxy, deprotecting a compound of formula (Xa):

 wherein R p together with the —OC(O)— group to which it is attached forms an ester; or

Process 7): for compounds of formula (I) wherein R 11 is a group of formula (IB) and N(R n )C(O)—; reacting an acid of formula (XIa):

 or an activated derivative thereof; with an amine of formula (XII):

and thereafter if necessary or desirable:

i) converting a compound of the formula (I) into another compound of the formula (I);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt.

13. A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 11 , in association with a pharmaceutically-acceptable diluent or carrier.

14. A compound selected from the group consisting of:

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)-α-carboxy-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

or a pharmaceutically acceptable salt thereof.

15. A compound selected from the group consisting of: a compound of formula (IXa):

 a compound of formula (IXb):

 a compound of formula (Xa):

 and a compound of formula (Xb):

wherein, in each said compound, R v , R 1 , R 2 , M, R x , R y , R z , R 3 , R 4 , R 5 , R 6 , X, Ring A, R 7 , R 8 , R 9 , R 10 , R 11 , Y, R 12 , R 13 , R 14 , R 15 , p, q, r, m, n, Ring B, R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 and R 26 are as defined in claim 1 , and R p is C 1-6 alkyl or phenylC 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.